Heyu Biological Technology Corporation (HYBT) financial statements (2021 and earlier)

Company profile

Business Address 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY
XIAMEN CITY, FUJIAN PROVINCE, 361022
State of Incorp. NV
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments34239645215698
Cash and cash equivalents34239645215698
Receivables65452384251024
Inventory, net of allowances, customer advances and progress billings48146747742231118818
Inventory48146747742231118818
Prepaid expense2766488163 
Advances on inventory purchases19      
Other undisclosed current assets  57    
Total current assets:596522586649869417141
Noncurrent Assets
Operating lease, right-of-use asset148160177203210  
Total noncurrent assets:148160177203210  
TOTAL ASSETS:7446827628521,079417141
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities254167150111000
Accounts payable17171481   
Accrued liabilities23715013631   
Taxes payable0000000
Deferred revenue485427437431420  
Debt  323166  
Due to related parties485427437431   
Other undisclosed current liabilities4894794184441,069842426
Total current liabilities:1,7131,4991,4741,4481,556842426
Noncurrent Liabilities
Long-term debt and lease obligation75128146173143  
Operating lease, liability75128146173143  
Other undisclosed noncurrent liabilities(75)(128)     
Total noncurrent liabilities:75128146173143  
Total liabilities:1,7871,6281,6211,6201,699842426
Stockholders' equity
Stockholders' equity attributable to parent(981)(884)(796)(716)(580)(407)(284)
Common stock1,0321,0321,0321,0321,0321,0321,032
Additional paid in capital17,14917,14917,14917,14917,14917,14917,149
Accumulated other comprehensive income (loss)(6)1618121763
Accumulated deficit(19,156)(19,081)(18,995)(18,910)(18,779)(18,594)(18,469)
Stockholders' equity attributable to noncontrolling interest(62)(62)(62)(52)(40)(18)(1)
Total stockholders' equity:(1,044)(946)(858)(768)(620)(425)(285)
TOTAL LIABILITIES AND EQUITY:7446827628521,079417141

Income statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues1734110672822
Cost of revenue(6)(17)(0)(52)(4)(15)(13)
Gross profit:11171554139
Operating expenses(88)(103)(95)(199)(208)(154)(58)
Operating loss:(77)(86)(94)(144)(205)(141)(48)
Nonoperating income (expense)(0)(0)(0)(0)(0)(1)0
Net loss:(78)(86)(94)(144)(205)(142)(48)
Net income attributable to noncontrolling interest2091320181
Net loss available to common stockholders, diluted:(75)(86)(86)(131)(185)(125)(48)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net loss:(78)(86)(94)(144)(205)(142)(48)
Other comprehensive income (loss)(25)(2)7(6)1321
Other undisclosed comprehensive income2091320181
Comprehensive loss:(100)(88)(79)(137)(172)(122)(47)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest20(1)1(1)(0)(0)
Comprehensive loss, net of tax, attributable to parent:(98)(87)(80)(136)(174)(122)(47)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: